Sign inJoin waitlistJoin the waitlist

Tanya Watt

Program Director, Pediatric Hematology/Oncology Fellowship · University of Texas Southwestern Medical Center

Credentials: · · · · ·

History

Pediatric Hematology/Oncology Fellowship · University of Texas Southwestern Medical Center
Present
University of Texas Southwestern Medical Center
Present
University of Texas Southwestern Medical Center
Present

Pediatric Hematology/Oncology
Emory University School of Medicine
2006–2009
Pediatrics
Emory University School of Medicine
2003–2006
Univ of Texas Sch of Med at San Antonio
1999–2003

Research

Radiation-Related New Primary Solid Cancers in the Childhood Cancer Survivor Study: Comparative Radiation Dose Response and Modification of Treatment Effects
International journal of radiation oncology · 2016 · 116 citations
Recent progress in the treatment of cancer in children
Review · Current Anthropology · 2021 · 97 citations
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024 · 96 citations

Theodore Laetsch
4 papers
Kieuhoa Vo
2 papers
Margaret Macy
2 papers
Patrick Leavey
2 papers
Steven DuBois
2 papers
Todd Cooper
2 papers
AeRang Kim
1 paper
Alanna Church
1 paper
Alexis Boulter
1 paper · 1 as a fellow
Ami Desai
1 paper
AR
Amulya Nageswara Rao
1 paper
Amy Garee
1 paper

Clinical trials

Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]
Principal investigator · Completed
University of Texas Southwestern Medical Center
2018–2024
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
Principal investigator · No longer available
University of Texas Southwestern Medical Center
Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
Study chair · Terminated · Phase 1
South Plains Oncology Consortium
2014–2018
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Site PI · Recruiting · Phase 1, Phase 2
Milton S. Hershey Medical Center
2026–2035